UCB withdraws EU application for expanded use of Vimpat

09/26/2008 | Reuters

The European Medicines Agency's negative review of Vimpat's use in diabetic neuropathic pain has prompted UCB SA to drop its EU application for the expanded use of the epilepsy treatment. A UCB spokeswoman said the Belgian drugmaker plans to conduct an additional clinical study "to further substantiate the magnitude" of Vimpat's effects in patients with diabetic neuropathic pain.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC